8/28/2008

Gleevec, Novartis' cancer drug, obtained priority-review status from the FDA as primary postsurgical treatment for gastrointestinal stromal tumors. The company is seeking approval based on clinical results showing that Gleevec lowered the risk of GIST after surgery by 89%.

Full Story:
Reuters

Related Summaries